Obermatt
See Similar Stocks →

Flags

Financial distress

Santhera Pharmaceuticals

SWX:SANN · CH1276028821
BiotechnologySmall

360

29
Profit price72
Owner Earnings Yield1
Dividend Yield1
Price/Sales46
EV / Gross Profit1
Price/Book97
Return on Capital37
Cash Return on Capital11
EBIT Margin51
Gross Profitability56
Accruals57
Owner Earnings Margin70
Sales growth65
Profit growth20
Reinvestment77
Price momentum69
Debt load5
Refinancing57
Debt Payback1
Liquidity30
Analyst ratings100
Opinion Changes50
Price Target Upside24
Market mood57
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Santhera Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySwitzerland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeSWX
Employees111
Websitesanthera.com
ISINCH1276028821
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
Chronic DiseasesNeurologyCentral Nervous SystemGenetic DisorderPulmonologyBiotechnologyHealth CarePharmaceutical

Description

Santhera Pharmaceuticals Holding AG focused on developing and commercializing innovative therapies for the treatment of neuromuscular and pulmonary diseases. Business Segments The company specializes in one primary segment: the development and comm…

Analysis

Middle-of-the-road

Santhera Pharmaceuticals Holding AG sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
68
2026

All-time high

68

Jun 2026

All-time low

61

Mar 2026

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
46
—
—
—
Price/Earnings
94
—
—
—
Price/Book
97
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
80
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Santhera Pharmaceuticals with its peers
Pharming
AEX:PHARM
77
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pentixapharm
GER:PTP
22
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Small
Full Stock Analysis →
NewAmsterdam Pharma Company
NMQ:NAMS
16
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
PolyPid
NAQ:PYPD
26
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Maison Pommery & Associes
PAR:POMRY
4
CountryFrance
IndustryBeverages
SizeSmall
Full Stock Analysis →
SHL Telemedicine
SWX:SHLTN
24
CountryIsrael
IndustryHealth Care Providers & Services
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →